2025-02-02 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Performance Review

**0. Overview:** Eli Lilly and Co. is a global pharmaceutical company that researches, develops, manufactures, and markets pharmaceutical products.  This report analyzes LLY's recent performance against the S&P 500 (VOO).


**1. Performance Comparison with S&P 500:**

LLY has significantly outperformed the S&P 500.  The cumulative return for LLY is 588.79%, while the S&P 500's cumulative return is 119.91%.  The difference is 468.9%, placing it at the 74.9th percentile of its historical relative performance against the S&P 500 (based on a historical range of 634.6% to -25.2%).


**Alpha and Beta Analysis:**

The provided data shows consistently high CAGR (Compound Annual Growth Rate) for LLY over several years, ranging from 9% to 396%.  Alpha, a measure of excess return compared to the benchmark, is mostly positive indicating outperformance. Beta, a measure of volatility relative to the market, remains relatively stable around 0.0-0.3, suggesting that LLY's price movements are less volatile than the overall market.  Note that these are historic data and future performance is not guaranteed.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 9.0% | 4.3% | -19.0% | -0.0 | 67.9 |
| 2016-2018  | 47.0% | 4.3% | 29.0% | 0.0 | 95.4 |
| 2017-2019  | 60.0% | 8.7% | 29.0% | 1.1 | 110.8 |
| 2018-2020  | 90.0% | 11.1% | 62.0% | 0.3 | 145.2 |
| 2019-2021  | 145.0% | 11.1% | 74.0% | 0.2 | 241.1 |
| 2020-2022  | 196.0% | 11.1% | 188.0% | 0.2 | 323.7 |
| 2021-2023  | 300.0% | 10.8% | 277.0% | 0.3 | 520.8 |
| 2022-2024  | 396.0% | 11.1% | 363.0% | 0.3 | 694.3 |
| 2023-2025  | 345.0% | 11.1% | 284.0% | 0.3 | 729.4 |


**2. Recent Price Movement:**

* **Closing Price:** $811.08
* **5-Day Moving Average:** $810.31
* **20-Day Moving Average:** $777.90
* **60-Day Moving Average:** $783.73

The price is currently slightly above the 5-day moving average, indicating short-term stability. However, it is significantly above both the 20-day and 60-day moving averages, suggesting a recent upward trend.  The closing price is lower than the previous close, showing a recent decrease of $12.15 (-1.47%).

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 52.57  - Suggests the stock is neither overbought nor oversold, indicating a neutral sentiment.
* **PPO (Percentage Price Oscillator):** 0.95  - A positive value indicates upward momentum.
* **Delta_Previous_Relative_Divergence:** +3.7  - This positive value suggests short-term upward price pressure.  The recent price drop, however, partially offsets this positive indication.
* **Expected Return:** 112.3%  - This suggests a significant potential for outperformance compared to the S&P 500 over a long-term (2+ years) investment horizon.

**4. Recent Earnings Analysis:**

The earnings data shows significant variability in EPS and revenue.  There's a large increase in EPS between Q2 and Q3 2024, which could warrant further investigation into the drivers of this change. A loss in EPS occurred in both November 2023 and October 2024 which should be investigated.

| 날짜 | EPS | 매출 |
|---|---|---|
| 2024-10-30 | 1.08 | 11.44 B$ |
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2024-10-30 | -0.06 | 9.50 B$ |


**5. Financial Information:**

Revenue has remained relatively stable over the past year, with slight fluctuations. Profit margins are consistently high, above 80%.  ROE (Return on Equity) shows considerable variation across quarters, possibly due to seasonal factors or one-time events.  Further investigation of these fluctuations is recommended.

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-09-30 | $11.44B | 81.02% |
| 2024-06-30 | $11.30B | 80.80% |
| 2024-03-31 | $8.77B | 80.91% |
| 2023-12-31 | $9.35B | 80.88% |
| 2023-09-30 | $9.50B | 80.42% |


**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-09-30 | $14.24B | 6.81% |
| 2024-06-30 | $13.56B | 21.88% |
| 2024-03-31 | $12.81B | 17.51% |
| 2023-12-31 | $10.77B | 20.33% |
| 2023-09-30 | $11.22B | -0.51% |


**6. Overall Analysis:**

LLY exhibits strong historical performance, significantly outperforming the S&P 500.  Positive alpha values and relatively low beta suggest consistent outperformance and lower volatility compared to the market.  Recent price movements show a recent upward trend despite a recent price drop.  Technical indicators suggest a neutral to positive outlook. However, recent earnings show high variability and require further investigation. The high profit margins and generally high ROE are positive signs.  The significant projected long-term expected return, coupled with the historically strong performance, makes LLY a potentially attractive investment, but further analysis of the variability in earnings and ROE is warranted before making any investment decisions.  This analysis is based on the limited data provided and should not be considered financial advice.
